Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Moximed

Biotech & Life Sciences · Hayward, United States · Founded 2006

Moximed is a medical technology startup that specializes in the development and distribution of the MISHA Knee System, an implantable shock absorber (ISA) for the knee. This innovative product is designed to alleviate pain and improve function for patients suffering from medial knee osteoarthritis (OA), a condition that causes pain and inflammation in the knee joint. The company's primary clients are healthcare providers who treat patients with knee OA, particularly those who have not found relief from non-surgical or surgical treatments, continue to experience pain that interferes with daily activities, or are ineligible for or unwilling to undergo arthroplasty (joint replacement surgery) due to age or absence of advanced arthritis. Moximed operates in the medical device market, a sector that is expected to grow as the global population ages and the prevalence of conditions like OA increases. The company's business model revolves around the sale of the MISHA Knee System to healthcare providers. The MISHA Knee System is marketed as a quick and efficient solution for knee OA, offering patients a swift recovery time and the ability to return to normal activities within days. This positions Moximed as a provider of innovative, patient-centric solutions that not only improve the quality of life for patients but also enhance the practice of healthcare providers who incorporate the MISHA Knee System into their treatment offerings. Keywords: Moximed, MISHA Knee System, Implantable Shock Absorber, Knee Osteoarthritis, Medical Technology, Healthcare Providers, Medical Device Market, Non-Surgical Treatment, Arthroplasty, Patient-Centric Solutions.

Valuation
$100–500M
Latest valuation · 2024
Unlock exact value
Headcount
<100
Current team size
Unlock exact value
Total funding Pre-IPO
$100–500M
Unlock exact value

Investors

16 investors on Moximed's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
ExploraMed
Series A 8 investors entered at this stage
NEA
Morgenthaler Ventures
Gilde Healthcare
Frazier Healthcare Partners
Vertex Holdings
Glide Health
GBS Venture Partners
Vertex Venture Capital
Series B+ 7 investors entered at this stage
Advent Life Sciences
Future Fund
Runway Growth Capital
Vertex Ventures HC
Warren Point Capital
Elevage Medical Technologies
Cormorant Asset Management

Global footprint

Where Moximed has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States98.5%
🇨🇭 Switzerland1.5%
2 countries shown

Talent graph

The shape of Moximed's talent

Dealroom maps Moximed's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

15 team members profilednamed & role-tagged by Dealroom
78 employeestotal headcount
3 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Moximed's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Moximed

An AI-synthesized read of the highest-engagement posts about Moximed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Moximed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.